Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Harvard Business School
Dow
McKesson
AstraZeneca

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

COREG CR Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Coreg Cr, and when can generic versions of Coreg Cr launch?

Coreg Cr is a drug marketed by Smithkline Beecham and is included in one NDA. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has fifty-one patent family members in seventeen countries.

The generic ingredient in COREG CR is carvedilol phosphate. There are thirty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.

Drug patent expirations by year for COREG CR
Drug Prices for COREG CR

See drug prices for COREG CR

Drug Sales Revenue Trends for COREG CR

See drug sales revenues for COREG CR

Recent Litigation for COREG CR

Identify potential future generic entrants

District Court Litigation
Case NameDate
GlaxoSmithKline LLC v. Glenmark Pharmaceuticals Inc., USA2014-07-03
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc.2014-07-03
FLAMEL TECHNOLOGIES S.A. v. LUPIN LIMITED2011-05-04

See all COREG CR litigation

Synonyms for COREG CR
(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol
[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine
1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol
1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol
1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
102641-EP2270011A1
102641-EP2272841A1
102641-EP2275420A1
102641-EP2298764A1
102641-EP2298765A1
102641-EP2301936A1
107741-96-8
2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-
72956-09-3
956C093
AB0008431
AB00639903_10
AB00639903_11
AB00639903_12
AB00639903-07
AB00639903-09
AB1004830
AC-1641
AC1L1E0B
AKOS005554967
AN-14749
API0001873
Artist
Artist (TN)
AX8120145
BBL029064
BC204100
BCP0726000253
BCP23386
BCP9000493
BDBM25759
BG0129
BM 14.190
BM 14190
BM-14-190
BM-14.190
BM-14190
BRD-A10977446-001-04-8
BRD-A10977446-001-05-5
BRD-A10977446-045-01-1
C-21835
C06875
C24H26N2O4
carvedilol
Carvedilol (JAN/USAN/INN)
Carvedilol [USAN:INN:BAN:JAN]
Carvedilol [USAN:USP:INN:BAN:JAN]
Carvedilol 1.0 mg/ml in Methanol
Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard
Carvedilol, >=98% (HPLC), solid
Carvedilol, European Pharmacopoeia (EP) Reference Standard
Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material
Carvedilol, United States Pharmacopeia (USP) Reference Standard
Carvedilolum
Carvedilolum [Latin]
CC-25436
CCG-100917
CCG-207952
CHEBI:3441
CHEMBL723
Coreg
Coreg (TN)
Coropress
CPD000449280
CS-1194
CTK3J2232
D00255
DB01136
Dibloc
Dilatrend
DQ 2466
DQ-2466
DTXSID8022747
EG-P042
Eucardic
FT-0603059
FT-0652640
GTPL551
HMS2051N03
HMS2089B09
HMS2093E12
HMS3261E15
HMS3269N11
HMS3393N03
HMS3655O14
HMS3715D15
HSDB 7044
HY-B0006
I06-0064
I06-1477
J10039
KB-75594
KBio2_002145
KBio2_004713
KBio2_007281
KBio3_002323
KBioGR_001252
KBioSS_002145
Kredex
KS-00000XRT
KS-1037
KSC492E3F
L001243
LP00347
LS-121875
MCULE-7944987271
MFCD00864692
MLS000758299
MLS000759508
MLS001424092
MLS006011886
MolPort-003-666-814
NC00167
NCGC00167832-01
NCGC00167832-02
NCGC00167832-03
NCGC00167832-04
NCGC00261032-01
NSC-758694
NSC758694
OGHNVEJMJSYVRP-UHFFFAOYSA-N
Pharmakon1600-01504257
PubChem18218
Q-200801
Querto
RTR-037608
s1831
SAM001246736
SAM001247021
SB17441
SBI-0206771.P001
SC-13445
SCHEMBL10082334
SCHEMBL13287211
SCHEMBL22293
SK&F-105517
SKF 105517
SMR000449280
SPBio_001885
Spectrum_001665
Spectrum2_001673
Spectrum3_001182
Spectrum4_000636
Spectrum5_001436
SR-01000759289
SR-01000759289-5
SR-01000759289-6
SR-01000759289-9
ST24036957
STK621453
SW197547-3
TL8005080
Tox21_500347
TR-037608
W-5131
Z2786051695
Paragraph IV (Patent) Challenges for COREG CR
Tradename Dosage Ingredient NDA Submissiondate
COREG CR CAPSULE, EXTENDED RELEASE;ORAL carvedilol phosphate 022012 2008-03-18
COREG CR CAPSULE, EXTENDED RELEASE;ORAL carvedilol phosphate 022012 2007-12-21
COREG CR CAPSULE, EXTENDED RELEASE;ORAL carvedilol phosphate 022012 2007-11-19

US Patents and Regulatory Information for COREG CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-004 Oct 20, 2006 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-002 Oct 20, 2006 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for COREG CR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-002 Oct 20, 2006   Start Trial   Start Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-002 Oct 20, 2006   Start Trial   Start Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Medtronic
McKesson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.